Navigation Links
Aranesp ``145 Study'' Shows No Difference in Survival in Patients,with Small-Cell Lung Cancer

ree-week dosing in these patients.

Important Safety Information including boxed WARNING

Use the lowest dose of Aranesp that will gradually increase the hemoglobin concentration to the lowest level sufficient to avoid the need for red blood cell transfusion.

Aranesp and other erythropoiesis-stimulating agents (ESAs) increased the risk for death and for serious cardiovascular events when administered to target a hemoglobin of greater than 12 g/dL.

Cancer Patients: Use of ESAs

-- Shortened the time to tumor progression in patients with advanced head and neck cancer receiving radiation therapy when administered to target a hemoglobin of greater than 12 g/dL,

-- Shortened overall survival and increased deaths attributed to disease progression at 4 months in patients with metastatic breast cancer receiving chemotherapy when administered to target a hemoglobin of greater than 12 g/dL,

-- Increased the risk of death when administered to target a hemoglobin of 12 g/dL in patients with active malignant disease receiving neither chemotherapy or radiation therapy. ESAs are not indicated for this population.

Patients receiving ESAs pre-operatively for reduction of allogeneic red blood cell transfusions: A higher incidence of deep venous thrombosis was documented in patients receiving Epoetin alfa who were not receiving prophylactic anticoagulation. Aranesp is not approved for this indication.

Aranesp is contraindicated in patients with uncontrolled hypertension. Aranesp and other erythropoietic therapies increase the risk of serious arterial and venous thromboembolic events, including myocardial infarction, stroke, congestive heart failure, and hemodialysis graft occlusion. A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may also contribute to these risks. To reduce cardiovascular risks, the hemoglobin (Hb) concentration should not exceed 12 g/dL, the rate of hemoglobin increase should not exceed 1 g/dL
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
(Date:12/1/2008)...EGO, Dec. 1 TargeGen has announced...s from a multi-center, US-based clinical,trial of...as been scheduled at,the 2008 American Society of...he presentation are as follows:, Title: ...oavailable, JAK2-Selective...
(Date:12/1/2008)...APOLIS, Dec. 1 Roche announced tod... differences in perceived pain and,discomfort ass...K blood,glucose monitoring systems and lancing de...indicated that, overall, the ACCU-CHEK Aviva and A...stems and the ACCU-CHEK Multiclix, ACCU-CHEK,Soft...
(Date:12/1/2008)...de study shows the Prox1 gene is a two-way switch ...cells to be reprogrammed so that they lose their i...ls , , MEMPHIS, Tenn., Dec. 1 /PRNewswire-U...esearch Hospital have discovered that a certain di...dentity that it requires the constant expression o...
(Date:12/1/2008)...TH MEETING, Pa., Dec. 1 ...nced that dosing of subjects has begun in study MS...se Phase 1b study of trodusquemine (MSI-1436) in o...a novel therapeutic for the treatment of type 2 di...herally to regulate insulin and leptin pathways th...
Breaking Medicine Technology:Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 2Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics 3Embryos Discarded During IVF Create Stem Cell Lines 10220 1Embryos Discarded During IVF Create Stem Cell Lines 10220 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 1Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 2Cancer Vaccine Consortium and Cancer Vaccine Collaborative unite under the Cancer Research Institute 10218 3The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 1The Beryl Companies Introduces New Customer Service Call Offering for Hospitals Nationwide 10216 2NutraCea Provides Update on Domestic Operations 10215 1NutraCea Provides Update on Domestic Operations 10215 2NutraCea Provides Update on Domestic Operations 10215 3
...g therapeutic cancer vaccine,trials have yet to sh... immune system to shrink tumors -- yet patients wh...nger and respond,better to subsequent treatment. I...journal of the American Association for Cancer,Res...hers asks a,fundamental question: are we looking a...
...)--Jul 5, 2007 - Australian,biotechnology company ...apricitabine,s controlled, double blinded phase wh...ase IIb trial.,Patients have now progressed into t...) and will continue to receive 800mg,apricitabine ...e.,The Company expects to release results from the...
Other Medicine Technology:From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 2From Clinical Cancer Research: Rethinking Therapeutic Cancer,Vaccine Trials 3Avexa's Apricitabine Clinical Trial Update 2
(Date:12/2/2008)...tes Healthy Habits , , NEW YORK, Dec. 2 /P...Bulletin Board: JNPC; "Juniper") Sorpresa! , Am...s network, will premiere its 60-minute live-action...max of the network,s seven-month initiative with M...M EST. , , The multifaceted program promote...
(Date:12/2/2008)... -- Neuralstem Inc.,(NYSE Alternext US: CUR) anno...ion with the China Medical University & Hospit...m,s human spinal cord neural stem cell,therapies....ral Sclerosis (ALS,or Lou Gehrig,s disease) with ...ator. , (Logo: http://www.newscom.com/cgi-...
(Date:12/2/2008)...n Medical Resources (AMR), a,provider of premier ...gnostic,imaging industries, finds that Ortho-McNe...rred quinolone antibiotic among more than half of ...ted States. Quinolone antibiotics are,used to tre...caused by,numerous bacterial pathogens. , ...
(Date:12/2/2008)...ents Will Double by 2017, According to a New Repor...., Dec. 2 Decision Resources, one ... for pharmaceutical and healthcare issues, finds t...-Cilag,s Stelara and Abbott/Eisai,s Humira, will d...to more than double to nearly $5 billion over the ...
Breaking Medicine News(10 mins):Health News:Sorpresa! Premieres Juega Como un MLS Pro 2Health News:Neuralstem Collaborates with Hospital in Taiwan to Develop Additional ALS Stem Cell Clinical Trials 2Health News:Levaquin is the Preferred Quinolone Among More Than Half of All General Medical-Surgical Hospitals in the United States 2Health News:Biologic Drugs, Particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai's Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017 2
...ormal breathing functions. Exposure to atmospheric...eart muscle during exercise in those with heart pr...ure to air pollution// with both heart disease and... the first to show how pollution can restrict the ...
...versity in Boston, a person's degree of inhibition...ies is tied to his or her likelihood of being over...--for example by choosing low-calorie foods--can h...tation to eat, according to lead investigator Dr. ...
...t common encountered among the mountaineers. Docto...rs are affected by altitude sickness and others ar...ung function may increase the risk of high altitud...e pulmonary edema (HAPE), can result when people c...
... consume wine in moderation have healthier lifesty...ther types of alcohol. It is well established tha...e health benefit,// chiefly in the form of reduced... may not be the alcohol itself, but linked lifesty...
Other Medicine News:Health News:Stop and think before you eat 2
Precision near-field imaging combined with the best handling IVUS catheter.
The Medison SonoAce 9900 is a fully digital, NT2000 based ultrasound system, with an integrated workstation that is DICOM compatible, designed for multi-specialty applications including general imagi
Full Digital Color Ultrasound
...armonic Echo technology constructs images using se...rtifacts and noise than fundamental-frequency comp...ogy to transmit distortion-free, fundamental-frequ...equency ultrasound beam is a pure sinusoidal wave,...
Medicine Products: